How Apple defends the app store in its biggest legal battle in years

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on pocket
Pocket
Share on whatsapp
WhatsApp
Morning Bullets header logo

Your daily source for trading strategies, tech news, and politically incorrect humor.

Hey there, Bullets Fans –

Your Morning Bullets Brief Updates are here! And that means trivia is, too.

May the Fourth be with you… Do you know the origin of this phrase? When was it first used?

Think you know the answer? You can check it in the closing area down below!

Five things to know before the market opens

Image Source: NYSE

Stock futures dipped slightly this morning, falling from yesterday’s rally.

Today, officials from Pfizer announced that it would apply for full vaccine approval in this country by month’s end. Should the company receive that approval, Pfizer would then have the ability to market its two-dose drug to consumers. Shares of the company were up 1.5% in the premarket on the news. Shares of CVS Health also shot up this morning after the company reported stellar earnings for the first quarter.

Tuesday also marks the beginning of restrictions for travelers coming from India, as that country navigates a surge in virus cases. There are more than 20 million cases right now.

What else should you know about the market before you start your day today?

Other News That Matters To You:

Here is why you don’t want to miss this once-in-a-lifetime opportunity

 

Recommended Link:
Six Stocks to Buy for the Coming Tech Boom 

Joe Biden just announced a $2.2 trillion infrastructure plan —

And it could send the value of certain tech stocks through the roof.

Louis Navellier — the analyst who MarketWatch said found Google first — just named six stocks set to soar thanks to this massive wave of spending…

You can get the name of all six stocks in Louis’ latest report, “Six Tech Stocks That Could Double.”

Just click here to claim your free report today.

 

Even after the blood-clot pause, Americans still want the J&J vaccine

Image Source: Reuters

A new survey shows that nearly 20% of Americans who have yet to get the vaccine will still opt for the Johnson & Johnson version, even after the blood-clot scare.

According to the latest data, about 17% of Americans say they’d prefer to receive the single-shot drug over either of the other, two-dose options. That number reflects a decrease from the 29% who felt this way back in March, before the blood clot issue.

The Food and Drug Administration and the Centers for Disease Control and Prevention initially recommended pausing the use of the Johnson & Johnson vaccine after some women experienced rare but severe blood clots after their vaccinations. That recommendation was lifted on April 23, after it was determined that the benefits dwarfed the risks.

What else does this survey show?

More Headline You Need To Read:

Thanks for reading once again! And don’t worry, I didn’t forget:

Here’s where you can go to check your answer!

Know someone who should be getting these Bullet Briefs? Make sure to send them over to www.morningbullets.com to subscribe.

Your biggest fan,

Image

Fredrick Frost

P.S.  How useful did you find today’s Morning Bullets? 

Not useful – 22.81%
It was ok – 13.11%
It was good – 38.31%
Very useful – 25.77%

Note: Percentages are updated once per week on Sundays and include all feedback since inception.

Fedrick Frost

Fedrick Frost

News Reporter for Morning Bullets, Writes on Politics, Economy, Business & More. Intrested in sharing news With Fredrick? Click Here

Never miss any important news. Subscribe to our newsletter.

Categories

Recent News

Welcome!

You are now part of the Morning bullets newsletter

let's save the world together